CORRESPONDENCE

Shortness of Breath and Cough in Patients in Palliative Care
by Prof. Dr. med. Claudia Bausewein PhD MSc, Dr. med. Steffen T. Simon MSc
in volume 33–34/2013

Connections Are Clearly More Complex
CME articles on palliative medicine are to be welcomed, since they are very important. In the article of Bausewein and Simon (1), the sections regarding drug treatment of palliative symptoms are appropriate and reflect the current state of knowledge.

Unfortunately, the authors did not stringently adhere to their stated objective of restricting the recommendations to patients with refractory dyspnea (for example, in the title, in the defined learning objectives on page 564, and in the algorithm on page 567). It is not stated clearly enough that the cited evidence is from studies that explicitly included only patients in whom tumor specific treatments (chemotherapy, radiotherapy, or surgery) was no longer indicated or not sufficiently effective.

From an oncological perspective, this limitation likely leads to considerable deficits, particularly regarding the care for patients in a palliative setting. The systematic evaluation of possible causes of dyspnea and cough is a crucial step towards the best possible treatment in the palliative setting. This is, for example, stated in the current US guidelines on palliative medicine published by the National Comprehensive Cancer Network (2). A plain chest x-ray (as suggested by Bausewein and Simon) will, for example, not be sufficient to detect pulmonary embolism, which is quite common in cancer patients, or malignant pericardial effusion.

Another important issue not covered by this article is the administration of local treatments such as radiotherapy. Radiotherapy is well recognized as a very effective local treatment generally associated with only minor adverse effects in the treatment of tumor or metastasis related dyspnea, cough, or hemoptysis. Furthermore, the aspect of communication with the patients was not appropriately mentioned. As described in the Canadian guidelines on the relief of dyspnea, preventive treatment of dyspnea should be initiated before a patient displays symptoms. This can be achieved by using structured education programs for patients and by discussing effective, symptom oriented treatment measures that can be applied when the malignant disease is progressing (3).

The process of multidisciplinary treatment decision making is mandatory in order to provide the most appropriate treatment approach for each individual cancer patient being in a palliative situation. Such a process requires a great expertise (4), which has been emphasized by the authors of this CME article. However, the authors have not mentioned important disciplines that can contribute very effectively to the relief of dyspnea in palliative cancer patients. The S3 guideline on palliative medicine that is currently under development will likely provide a more comprehensive perspective.

DOI: 10.3238/arztebl.2013.0753a

REFERENCES

Dr. med. Birgitt van Oorschot
Interdisziplinäres Zentrum Palliativmedizin
Universitätsklinikum Würzburg
Oorschot_bi@ukw.de

Prof. Dr. med. Dirk Rades
Klinik für Strahlentherapie
Universitätsklinikum Lübeck
für die Arbeitsgemeinschaft Palliative Strahlentherapie
und Palliativmedizin der DEGRO

Prof. Dr. med. Florian Lendick
Universitäres Krebszentrum Leipzig
für die Arbeitsgemeinschaft Palliativmedizin der Deutschen Krebsgesellschaft (APM)

Conflict of interest statement
The authors declare that no conflict of interest exists.

In Reply:
We thank our correspondents for emphasizing that the therapeutic recommendations in our article are related to refractory dyspnea and cough, as mentioned in our subheadings and the introduction.

Our corresponding colleagues support our opinion that potentially reversible causes of shortness of breath and cough need to be identified in order to be able to use all causal therapeutic options. A number of diagnostic measures are available to this end. We think that a comprehensive differential diagnostic evaluation is the remit of the leading medical specialty (for example, oncology, pneumology) and therefore

Deutsches Ärzteblatt International  Dtsch Arztebl Int 2013; 110(44)
restricted ourselves to selected examples of diagnostics from the perspective of palliative medicine. Close collaboration among the different specialties is important while recognizing one another’s technical competence, and, in our experience, this has become a good tradition in palliative medicine—entirely in the sense of an “interdisciplinary treatment approach.”

Specific local therapeutic options, such as the mentioned radiotherapy or bronchoscopy are among the disease-specific options that should already have been exhausted or should not be indicated in refractory dyspnea.

As we explained in detail in our sections on history taking and evaluation and general measures, the different aspects of communication with patients and their families are a crucial component in caring for patients with refractory dyspnea. This ranges from careful listening, to the question of whether a patient or family member is experiencing any psychological distress, to showing options for tackling dyspnea and creating and explaining an emergency plan. The suggestion of “preventive” communication is helpful if it is foreseeable that a patient will develop dyspnea.

DOI: 10.3238/arztebl.2013.0753b

REFERENCES

Prof. Dr. med. Claudia Bausewein PhD MSc
Klinik und Poliklinik für Palliativmedizin
Klinikum der Universität München
claudia.bausewein@med.uni-muenchen.de

Dr. med. Steffen Simon MSc
Zentrum für Palliativmedizin
Universitätsklinikum Köln

Conflict of interest statement
Prof. Bausewein has received support for a research project that she initiated from the National Institutes of Health Research (NIHR) and from Cicely Saunders International. She has received payment for preparing continuing medical education events from the Association for Lung Disease and Tuberculosis (Verein zur Förderung der Lungen- und Tuberkuloseheilkunde), the Evangelische Lungenklinik in Berlin and the Health Professions Education Center and Doctors’ Academy (Bildungszentrum für Gesundheitsberufe mit Ärzteakademie) in Hamburg. She has received reimbursement of conference participation fees and travel and accommodation costs from the European Association for Palliative Care, the German Association for Palliative Medicine (Deutsche Gesellschaft für Palliativmedizin), and the German Respiratory Society (Deutsche Gesellschaft für Pneumologie).

Dr. Simon has received funding from TEVA for a research project that he initiated.